Tag: MNKD

FB Nasdaq FB Facebook
Finance

New Highs: OmniVision Technologies, Inc. (NASDAQ:OVTI), MannKind Corporation (NASDAQ:MNKD), Intel Corporation (NASDAQ:INTC), Sabre Corp (NASDAQ:SABR)

OmniVision Technologies Inc. (NASDAQ:OVTI) is a publicly traded company with a stock that is set to rocket higher. Revenues for the fourth quarter of fiscal 2014 were $331 million compared to $352 million in the third quarter of fiscal 2014 and $336.2 million in the fourth quarter of fiscal 2013. GAAP net income in the fourth quarter of fiscal 2014 was $15.1 million, or 26 … Continue reading New Highs: OmniVision Technologies, Inc. (NASDAQ:OVTI), MannKind Corporation (NASDAQ:MNKD), Intel Corporation (NASDAQ:INTC), Sabre Corp (NASDAQ:SABR)

Colin Pettis
Finance

Stocks To Watch: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), Galena Biopharma Inc (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Effective May 15, 2014, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) granted an exemption to BlackRock, Inc. (NYSE: BLK), together with its subsidiaries, affiliates and associates (collectively, “BlackRock”) under the Company’s Section 382 Rights Agreement, dated as of October 31, 2013, between the Company and Computershare Trust Company, N.A., as rights agent (the “Rights Agreement”) following the determination by a designated committee of the Board of Directors (the … Continue reading Stocks To Watch: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), Galena Biopharma Inc (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Jason Knox
Finance

Healthcare ACtive Stocks: Rexahn Pharmaceuticals (NYSEMKT:RNN), Eli Lilly (NYSE:LLY), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Gentiva Health Services (NASDAQ:GTIV)

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) said, “We continue to enroll patients in each of our three clinical trials as expected, and as planned for. By the end of 2014, we expect to achieve key milestones in each trial. In Q4 we expect to have data from our Phase I trial of Supinoxin in cancer patients with solid tumors. We are also scheduled to complete enrollment of … Continue reading Healthcare ACtive Stocks: Rexahn Pharmaceuticals (NYSEMKT:RNN), Eli Lilly (NYSE:LLY), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Gentiva Health Services (NASDAQ:GTIV)

Colin Pettis
Finance

Biotech Gainers: MannKind Corporation (NASDAQ:MNKD), Celldex Therapeutics (NASDAQ:CLDX), Dendreon Corporation (NASDAQ:DNDN), Intrexon Corp (NYSE:XON)

MannKind Corp. (NASDAQ: MNKD) was raised to Neutral from Underweight by Piper Jaffray. MannKind Corporation (NASDAQ:MNKD) stock performance was 6.53% in last session and finished the day at $7.01. Traded volume was 16.68million shares in the last session and the average volume of the stock remained 10.11million shares. The beta of the stock remained 1.40. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.30%. Celldex Therapeutics, Inc. … Continue reading Biotech Gainers: MannKind Corporation (NASDAQ:MNKD), Celldex Therapeutics (NASDAQ:CLDX), Dendreon Corporation (NASDAQ:DNDN), Intrexon Corp (NYSE:XON)

Mark DeFrance
Finance

Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE)’s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses, but promised to keep key research jobs in Britain as part of its $106 billion takeover bid. Pfizer Inc. (NYSE:PFE) stock performance was 0.24% in last session and finished the day at $29.20. Traded volume was 26.29million shares in the last session and the average volume of … Continue reading Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis
Finance

Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

MannKind Corporation (NASDAQ:MNKD) loss of 14 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate by a penny but narrower than the year-ago loss by a penny. MannKind Corporation (NASDAQ:MNKD) did not generate any revenue in the first quarter of 2014, as in the year-ago quarter. Research and development (R&D) expenses remained flat at $26.2 million in the … Continue reading Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

Adam Keintzel